CN1726193A

CN1726193A - Heterocycle SARM and using method thereof

Info

Publication number: CN1726193A
Application number: CNA2003801061407A
Authority: CN
Inventors: 詹姆斯·T.·多尔顿; 杜安·D.·米勒
Original assignee: University of Tennessee Research Foundation
Current assignee: University of Tennessee Research Foundation
Priority date: 2002-10-15
Filing date: 2003-10-14
Publication date: 2006-01-25
Also published as: WO2004035737A2; EP1562906A4; US20070265290A1; AU2003287076B2; EP1562906A2; TW200502249A; CA2501867A1; AU2003287076C1; US20040138244A1; US7214693B2; AU2009202683A1; AU2003287076A2; JP2006518328A; AU2003287076A1; WO2004035737A3

Abstract

The invention provides androgen receptor target agent (ARTA).This medicine is a new subclass compound, and they are SARM (SARM).Found that several SARM compounds have the short male and anabolic activity of unexpected on-steroidal part to androgen receptor.Found that other SARM compound has the androgen antagonist activity of unexpected on-steroidal part to androgen receptor.The SARM compound is used for a) male contraception separately or as composition; B) the multiple and hormone-related conditions of treatment, for example reduce (ADAM) relevant illness, as fatigue, depression, sexual desire reduction, sexual dysfunction, erective dysfunction, hypogonadism, osteoporosis, alopecia, anaemia, obesity, senile amyotrophy, osteopenia, osteoporosis, benign prostatic hyperplasia, mood and cognitive change and prostate cancer with old male sex's male sex hormone; C) treatment reduces (ADIF) relevant illness with women's male sex hormone, as sexual dysfunction, sexual desire reduction, hypogonadism, senile amyotrophy, osteopenia, osteoporosis, mood and cognitive change, depression, anaemia, alopecia, obesity, endometriosis, mammary cancer, uterus carcinoma and ovarian cancer; D) treat and/or prevent acute and/or chronic wasting disease; E) prevent and/or treat xeropthalmus; F) oral androgenic replacement therapy; G) sickness rate of reduction prostate cancer stops prostate cancer or causes prostate cancer to disappear; And/or h) apoptosis in the inducing cancer cell.

Description

Heterocycle SARM and using method thereof

Technical field

The present invention relates to the androgen receptor target agent (ARTA) of novel type, they are SARM (SARM).These SARM compounds can be used for a) male contraception; B) the multiple and hormone-related conditions of treatment, for example reduce (ADAM) relevant illness, as fatigue, depression, sexual desire reduction, sexual dysfunction, erective dysfunction, hypogonadism, osteoporosis, alopecia, anaemia, obesity, senile amyotrophy, osteopenia, osteoporosis, benign prostatic hyperplasia, mood and cognitive change and prostate cancer with old male sex's male sex hormone; C) treatment reduces (ADIF) relevant illness with women's male sex hormone, as sexual dysfunction, sexual desire reduction, hypogonadism, senile amyotrophy, osteopenia, osteoporosis, mood and cognitive change, depression, anaemia, alopecia, obesity, endometriosis, mammary cancer, uterus carcinoma and ovarian cancer; D) treat and/or prevent acute and/or chronic wasting disease; E) prevent and/or treat xeropthalmus; F) oral androgenic replacement therapy; G) sickness rate of reduction prostate cancer stops prostate cancer or causes prostate cancer to disappear; And/or h) apoptosis in the inducing cancer cell.

Background technology

Androgen receptor (" AR ") is a part activated transcription regulatory protein, and it is induced by its endogenous androgenic activity mediation male sex's sexual development and function.Male sex hormone is commonly called androgen.Male sex hormone is to be produced in vivo by testis and adrenal cortex, perhaps can be in the laboratory synthetic steroid.Androgenic steroids plays an important role in many physiological processs, comprise the growth that male sex characteristics such as muscle and bone amount, prostate gland growth, spermatogeny and male sex's hair distribute and keep (Matsumoto, Endocnnol.Met.Clin.N Am.23:857-75 (1994)).Endogenous steroid male sex hormone comprises testosterone and dihydrotestosterone (" DHT ").Testosterone is the main steroid by testicular secretion, and is the main circulation male sex hormone of finding in male blood plasma.In many peripheral tissues, testosterone is changed into DHT by the enzyme 5.Therefore think that for most of androgenic effects, DHT plays a part medium in born of the same parents people such as (, Molec.Endocrinol.9:208-18 (1995)) Zhou.Other steroid male sex hormone comprises the ester of testosterone, as cipionate, propionic ester, phenylpropionic acid ester, cyclopentanepropanoiacid acid ester, isocarporate, heptanoate and decylate, and other synthetic androgen, as 7-methylnortestosterone (" MENT ") and acetic ester thereof) (people such as Sundaram, " 7 Alpha-Methyl-Nortestosterone (MENT): The Optimal Androgen For Male Contraception; " Ann.Med, 25:199-205 (1993) (" Sundaram ")).Owing to relate to AR in male sex's sexual development and function, AR is likely the target of the hormone replacement therapy of realizing male contraception or other form.

The social consciousness of worldwide population growth and birth control has encouraged people to carry out big quantity research at contraception.Contraception under any circumstance all is a difficult problem.It is full of culture and society branding, religion involve, and the most definite be great healthy effect.When theme concentrated on male contraception, these situations only can more be aggravated.Although suitable contraceptive device is arranged, in history, society expects that still the women shoulders the responsibility of contraception decision and its consequence.Though make the male sex have recognized the need to form safe and responsible sexual custom more for the consideration to sexually transmitted disease (STD), the women still usually bears the pressure that contraception is selected.The women has many selections, from temporary transient mechanical implement such as sponge and barrier film to temporary transient chemical utensil such as spermicide.The women also has the more persistent selection that arranged by they, as comprises the physics utensil of IUD and Diaphragm contraceptive, and such as the more persistent chemotherapy of oral contraceptive and hypodermic implant.Yet up to now, the only selection of man comprises uses condom and vasotomy., because minimizing property susceptibility, disruptive is spontaneous and cause pregnant obvious possibility because of breaking or misapply, so many man's disapproves use condom.Vasotomy is also agreed with.If the man has the long-acting method that need not prolusion before the contraceptive device more easily, particularly sexual behaviour at once, these class methods can increase the man bears more responsibilities to contraception possibility significantly.

In this regard, give male sex's steroid (for example testosterone and derivative thereof) and demonstrated special hope, this is because these compounds have suppresses gonad-stimulating hormone and substitute androgenic association property (people such as Steinbefger, " Effect of Chronic Administration of TestosteroneEnanthate on Sperm Production and Plasma Testosterone; Follicle StimulatingHormone; and Luteinizing Hormone Levels:A Preliminary Evaluation of aPossible Male Contraceptive, Fertility and Sterility 28:1320-28 (1977)).Giving the high dosage testosterone for a long time eliminates sperm generation (no sperm) fully or makes oligospermia to the utmost point low-level (oligospermia).The degree that suppresses for the sterile required spermatogeny of generation does not know for sure.Yet, recently the report of the World Health Organization shows, intramuscularly testosterone heptanoate causes no sperm or serious oligospermia (be every milliliter less than 3,000,000 sperms) and sterile (World Health Organization Task Force on Methods and Regulation ofMale Fertility in 98% the man who receives treatment weekly, " Contraceptive Efficacy of Testosterone-Induced Azoospermiaand Oligospermia in Normal Men, " Fertility and Sterility 65:821-29 (1996)).

Be absorbed after having developed intramuscularly slowlyer, therefore, cause the various testosterone esters of stronger short male function.In these esters, the testosterone heptanoate is most widely used.Though it is valuable that the testosterone heptanoate is used in foundation aspect the feasibility of hormone drug of male contraception, but it has some defectives, comprise need inject weekly with intramuscularly after the testosterone that occurs immediately excusing from death reason peak level have (a Wu, " Effects of Testosterone Enanthate in Normal Men:Experience From aMulticenter Contraceptive Efficacy Study, " Fertility and Sterility 65:626-36 (1996)).

In conjunction with AR and serve as androgenic steroid part (for example testosterone heptanoate) or serve as the steroid part (for example cyproterone acetate) of androgen antagonist for many years known, and use (Wu1988) clinically.Although the on-steroidal androgen antagonist is used for the hormonal dependent prostate cancer clinically,, still there is not the androgenic report of on-steroidal.Therefore, the research to male contraceptive pill mainly concentrates on the steroide.

In the American, prostate cancer is one of cancer of the most normal generation, diagnoses out hundreds thousand of new cases every year.Unfortunately, have in the cases for prostate cancer of new diagnosis that discovery is to develop on the pathology 60% or more, can't cure and prognosis not good.An approach that addresses this problem is by screening procedure early discovery prostate cancer, thereby reduces the number of the patients with prostate cancer of development.Yet other method is that developing drugs is prevented prostate cancer.1/3 prostate cancer of suffering from potential form is arranged among the male sex more than 50 years old, and it may be activated into life-threatening clinical prostate cancer form.Between the fifties to the nineties, the occurrence frequency of potential tumor of prostate all significantly increased in per ten years, and be 5.3-14% the fifties, and be 40-80% the nineties.People's the number of suffering from potential prostate cancer is identical between literate, the ethnic group of institute and race, yet the occurrence frequency of clinical aggressive cancer is significantly different.This shows that environmental factors works in activating potential prostate cancer.Therefore, the exploitation of treatment of prostate cancer and prevention method may have maximum holistic medicine and economic implications to the control of prostate cancer.

Osteoporosis is a kind of general skeletal diseases, it is characterized in that low bone amount and osseous tissue deterioration, and bone fragility increases and fractures easily as a result.In the U.S., this illness influences greater than 2,500 ten thousand people, and causes annual about 1,300,000 example fracture, comprises annual 500000 routine spinal fractures, 250000 hip fractures and 240000 routine carpal fractures.Hip fracture is osteoporotic serious consequence, has the patient of 5-20% dead in 1 year, surpasses survivor's incompetence of 50%.Senior people generally has maximum osteoporosis danger, therefore, estimates that this problem significantly increases with aging population.Estimate that worldwide fracture sickness rate increased by three times in 60 years subsequently, and the research estimation the year two thousand fifty whole world will there be about 4,500,000 routine hip fractures.

The osteoporotic risk of women is greater than the male sex.Women's in-seam loss in 5 years after menopause is obviously quickened.Other factor that increases risk comprises smoking, alcohol abuse, sedentary lifestyle and the absorption of low calcium.But osteoporosis also often takes place in the male sex.Determine that clearly male sex's bone mineral density reduces with the age increase.The reduction of bone mineral content and density is relevant with the bone strength reduction, and easily fractures.The molecule mechanism of sexual hormoue pleiotropic effects in non-germinal tissue has just begun to be familiar with, but male sex hormone and estrogenic physiological concentration play an important role to the maintenance of bone stable state in whole life.Therefore, when male sex hormone or oestrogenic hormon forfeiture generation, consequently bone remodeling speed increases, and the balance that absorbs and form is tilted for helping absorption, and this causes whole bone amount loss.In the male sex, the reducing naturally of maturity hormone (androgenic direct minimizing with derived from androgenic periphery aromizing than the low estrogen level) relevant with the bone fragility.This effect is also observed in the castrating male sex.

Old male sex's male sex hormone reduces the progressive minimizing that (ADAM) refers to that male sex hormone produces, and is common in the male sex after the middle age.This illness feature is the change of health and intellectual aspect, and it is relevant with the male sex hormone environment and can correct by control male sex hormone environment.The biochemical characteristics of ADAM is that not only serum androgen reduces, and other hormone such as tethelin, melatonin and dehydrotransandrosterone also reduce.Clinical manifestation comprises fatigue, depression, sexual desire reduction, sexual dysfunction, erective dysfunction, hypogonadism, osteoporosis, alopecia, obesity, senile amyotrophy (sarcopenia), osteopenia, benign prostatic hyperplasia, anaemia, mood and cognitive change and prostate cancer.

Women's hypoandrogenism (ADIF) refers to multiple and hormone-related conditions, comprises common illness among the middle age back women.The feature of this illness is sexual dysfunction, sexual desire reduction, hypogonadism, senile amyotrophy, osteopenia, osteoporosis, cognition and mood change, anaemia, depression, anaemia, alopecia, obesity, endometriosis, mammary cancer, uterus carcinoma and ovarian cancer.

Wasting disease refers to muscle quality progressive loss and/or muscle, and what comprise the cardiac muscle (myocardosis) of the skeleton of controls movement or voluntary muscle, control heart and unstriated muscle progressively dies down and degenerate.Chronic wasting disease is chronic disease (promptly continue segment length's time), it is characterized in that the progressive loss of muscle quality, the dying down and degenerate of muscle.The feature of the loss of muscle mass that takes place during wasting disease is that myoprotein decomposes or degraded.The reason that protein degradation takes place is high unusually protein degradation speed, low protein synthesis speed unusually, the perhaps combination of the two.Protein degradation no matter be to be caused or caused by the synthetic degree of lower protein by the high protein degree of degradation, all causes muscle quality to reduce and wasting disease.Wasting disease is relevant with chronic, nervosa, reproducibility or infectivity pathology, disease, slight illness or illness.These comprise muscular dystrophy, as bulbar paralysis muscular dystrophy and myotonia atrophica; Muscular atrophy is as muscular atrophy after the poliomyelitis (PPMA); Emaciation is as heart emaciation, AIDS emaciation and cancer cachexia, malnutrition, leprosy, diabetes, ephrosis, chronic obstructive pulmonary disease (COPD), cancer, renal failure in latter stage, pulmonary emphysema, richets, HIV infection, AIDS and myocardosis.In addition, other environment is relevant with wasting disease with illness, and can cause wasting disease.These comprise chronic back pain, advanced age, central nervous system (CNS) damage, peripheral nerve injury, Spinal injury, chemical damage, central nervous system (CNS) damage, peripheral nerve injury, Spinal injury, chemical damage, burn, fix at four limbs, since ailing or damage cause taking place when being in hospital for a long time stop using deadaptation and alcoholism.If the unabated words of wasting disease have terrible consequences.For example, the variation that takes place during wasting disease may cause physical appearance to die down, and this is harmful to health of individuality, cause to the susceptibility that infects increase, behavior state is bad and easy damaged.

Need new innovative method to develop in a hurry in basic science and clinical level and be used for following compound: a) male contraception; B) the multiple and hormone-related conditions of treatment, for example reduce (ADAM) relevant illness, as fatigue, depression, sexual desire reduction, sexual dysfunction, erective dysfunction, hypogonadism, osteoporosis, alopecia, anaemia, obesity, senile amyotrophy, osteopenia, osteoporosis, benign prostatic hyperplasia, mood and cognitive change and prostate cancer with old male sex's male sex hormone; C) the treatment illness relevant with ADIF is as sexual dysfunction, sexual desire reduction, hypogonadism, senile amyotrophy, osteopenia, osteoporosis, mood and cognitive change, depression, anaemia, alopecia, obesity, endometriosis, mammary cancer, uterus carcinoma and ovarian cancer; D) treat and/or prevent acute and/or chronic wasting disease; E) prevent and/or treat xeropthalmus; F) oral androgenic replacement therapy; G) sickness rate of reduction prostate cancer stops prostate cancer or causes prostate cancer to disappear; And/or h) apoptosis in the inducing cancer cell.

Summary of the invention

In one embodiment, the invention provides SARM (SARM) compound that the structure of formula I is represented:

Wherein

X is a key, O, CH ₂, NH, Se, PR, NO or NR;

G is O or S:

R ₁Be CH ₃, CH ₂F, CHF ₂, CF ₃, CH ₂CH ₃, or CF ₂CF ₃

T be OH, OR ,-NHCOCH ₃, or NHCOR;

R is alkyl, haloalkyl, dihalo alkyl, tri haloalkyl, CH ₂F, CHF ₂, CF ₃, CF ₂CF ₃, aryl, phenyl, F, Cl, Br, I, thiazolinyl or OH;

A is selected from following ring:

B is selected from following ring:

With

Wherein A and B can not be phenyl ring simultaneously;

Z is NO ₂, CN, COOH, COR, NHCOR or CONHR;

Y is CF ₃, F, I, Br, Cl, CNCR ₃Or SnR ₃

Q ₁And Q ₂Be hydrogen, alkyl, F, Cl, Br, I, CF independently of each other ₃, CNCR ₃, SnR ₃, NR ₂, NHCOCH ₃, NHCOCF ₃, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH ₃, NHCSCF ₃, NHCSRNHSO ₂CH ₃, NHSO ₂R, OR, COR, OCOR, OSO ₂R, SO ₂R, SR,

Q ₃And Q ₄Be hydrogen, alkyl, F, Cl, Br, I, CF independently of each other ₃, CNCR ₃, SnR ₃, NR ₂, NHCOCH ₃, NHCOCF ₃, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH ₃, NHCSCF ₃, NHCSRNHSO ₂CH ₃, NHSO ₂R, OR, COR, OCOR, OSO ₂R, SO ₂R or SR;

W ₁Be O, NH, NR, NO or S; And

W ₂Be N or NO.

In another embodiment, the invention provides analogue, isomer, metabolite, derivative, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, impurity, prodrug, polymorph or crystal or their arbitrary combination of formula I compound.

In one embodiment, the X in the Compound I is O.In one embodiment, the G in the Compound I is O.In another embodiment, the T in the Compound I is OH.In another embodiment, the R in the Compound I ₁Be CH ₃In another embodiment, the Z in the Compound I is NO ₂In another embodiment, the Z in the Compound I is CN.In another embodiment, the Y in the Compound I is CF ₃In another embodiment, the Q in the Compound I ₁Be NHCOCH ₃In another embodiment, the Q in the Compound I ₁Be F.

In another embodiment, the compound of formula I is represented with the structure of formula Ia:

Wherein A and B such as above-mentioned Compound I define.

In one embodiment, the A in the Compound I is:

In another embodiment, the A in the Compound I is:

Or

In one embodiment, the B in the Compound I is:

In another embodiment, the B in the Compound I is:

In another embodiment, the B in the Compound I is:

Or

In one embodiment, the present invention further provides SARM (SARM) compound that the structure of formula II is represented:

Wherein

X is a key, O, CH ₂, NH, Se, PR, NO or NR;

G is O or S;

R ₁Be CH ₃, CH ₂F, CHF ₂, CF ₃, CH ₂CH ₃, or CF ₂CF ₃

T be OH, OR ,-NHCOCH ₃, or NHCOR,

B is selected from following ring:

With

Z is NO ₂, CN, COOH, COR, NHCOR or CONHR;

Y is CF ₃, F, I, Br, Cl, CNCR ₃Or SnR ₃

W ₁Be O, NH, NR, NO or S; And

W ₂Be N or NO.

In another embodiment, the invention provides analogue, isomer, metabolite, derivative, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, impurity, prodrug, polymorph or crystal or their arbitrary combination of formula II compound.

In one embodiment, the X among the Compound I I is O.In one embodiment, the G among the Compound I I is O.In another embodiment, the T among the Compound I I is OH.In another embodiment, the R among the Compound I I ₁Be CH ₃In another embodiment, the Z among the Compound I I is NO ₂In another embodiment, the Z among the Compound I I is CN.In another embodiment, the Y among the Compound I I is CF ₃In another embodiment, the Q among the Compound I I ₁Be NHCOCH ₃In another embodiment, the Q among the Compound I I ₁Be F.

In one embodiment, the SARM compound is to represent with the structure of formula III, and wherein B and X such as above-mentioned formula II define:

In another embodiment, the SARM compound is to represent with the structure of formula IV, and wherein B and X such as above-mentioned formula II define:

In another embodiment, the SARM compound is represented by following structure:

Or

In another embodiment, the SARM compound is represented by following structure:

In another embodiment, the SARM compound is represented by following structure:

In one embodiment, the present invention further provides by SARM (SARM) compound of representing with following formula V structure:

Wherein

X is a key, O, CH ₂, NH, Se, PR, NO or NR;

G is O or S;

R ₁Be CH ₃, CH ₂F, CHF ₂, CF ₃, CH ₂CH ₃, or CF ₂CF ₃

T be OH, OR ,-NHCOCH ₃, or NHCOR;

A is selected from following ring:

With

Z is NO ₂, CN, COOH, COR, NHCOR or CONHR;

Y is CF ₃, F, I, Br, Cl, CNCR ₃Or SnR ₃

W ₁Be O, NH, NR, NO or S; And

W ₂Be N or NO.

In another embodiment, the invention provides analogue, isomer, metabolite, derivative, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, impurity, prodrug, polymorph or crystal or their arbitrary combination of formula V compound.

In one embodiment, the X among the compound V is O.In one embodiment, the G among the compound V is O.In another embodiment, the T among the compound V is OH.In another embodiment, the R among the compound V ₁Be CH ₃In another embodiment, the Z among the compound V is NO ₂In another embodiment, the Z among the compound V is CN.In another embodiment, the Y among the compound V is CF ₃In another embodiment, the Q among the compound V ₁Be NHCOCH ₃In another embodiment, the Q among the compound V ₁Be F.

In another embodiment, SARM compound of the present invention represents that in order to the structure of following formula VI wherein A and X such as above-mentioned formula V define:

In another embodiment, the SARM compound is represented by following structure:

Or

In another embodiment, the SARM compound is represented by following structure:

In another embodiment, the SARM compound is represented by following structure:

In another embodiment, the SARM compound is represented by following structure:

In another embodiment, the SARM compound is represented by following structure:

In another embodiment, the SARM compound is represented by following structure:

Or

In another embodiment, the SARM compound is represented by following structure:

Or

In another embodiment, the SARM compound is represented by following structure:

Or

In another embodiment, the SARM compound is represented by following structure:

Or

In one embodiment, the invention provides the SARM compound that comprises one of formula I-VI and/or the composition of its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination.

In one embodiment, the invention provides the SARM compound and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination that comprise one of formula I-VI, and the composition of suitable carriers or thinner.

In another embodiment, the invention provides the SARM compound and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination that comprise one of formula I-VI, and the pharmaceutical composition of suitable carriers or thinner.

In another embodiment, the invention provides a kind of SARM compound and androgen receptor bonded method of making, it may further comprise the steps: the SARM compound of androgen receptor and one of formula I-VI that makes SARM compound and androgen receptor bonded amount effectively and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination are contacted

In another embodiment, the invention provides spermatogenetic method in a kind of inhibition individuality, it may further comprise the steps: the SARM compound of the androgen receptor that makes described individuality and one of formula I-VI that effectively suppresses the amount that sperm produces and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination contact.

In another embodiment, the invention provides a kind of male individual method of contraception that makes, it may further comprise the steps: thus effectively suppress SARM compound and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination that described individual sperm produces one of the formula I-VI of the amount that causes described individual contraception to described individual administration.

In another embodiment, the invention provides a kind of methods of hormonal treatment, it may further comprise the steps: the SARM compound of one of formula I-VI of individual androgen receptor and the amount that effectively causes the change of androgen-dependent illness and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination are contacted.

In another embodiment, the invention provides a kind of hormone replacement therapy method, it may further comprise the steps: the SARM compound of one of formula I-VI of individual androgen receptor and the amount that effectively causes the change of androgen-dependent illness and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination are contacted.

In another embodiment, the invention provides a kind of treatment and suffer from method with the individuality of hormone-related conditions, it may further comprise the steps: the SARM compound from one of the formula I-VI of the amount that the androgen-dependent illness changes to described individual administration and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination that effectively cause.

In another embodiment, the invention provides a kind of treatment and suffer from the method for the individuality of prostate cancer, it may further comprise the steps SARM compound and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination to one of formula I-VI of the amount of the described individual prostate cancer of the effective treatment of described individual administration.

In another embodiment, the invention provides a kind of method of preventing individual prostate cancer, it may further comprise the steps: to described individual administration effectively SARM compound and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination of one of the formula I-VI of the amount of the described individual prostate cancer of prevention.

In another embodiment, the invention provides the method for prostate cancer development in a kind of individuality that delays to suffer from prostate cancer, it may further comprise the steps: effectively delay SARM compound and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination of one of the formula I-VI of the amount of prostate cancer development in the described individuality to described individual administration.

In another embodiment, the invention provides the method for prostate cancer recurrence in a kind of individuality that prevents to suffer from prostate cancer, it may further comprise the steps: effectively prevent SARM compound and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination of one of the formula I-VI of the amount of prostate cancer recurrence in the described individuality to described individual administration.

In another embodiment, the invention provides a kind of treatment and suffer from the method for prostate cancer recurrence in the individuality of prostate cancer, it may further comprise the steps: SARM compound and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination of one of formula I-VI of the amount of prostate cancer recurrence in the described individuality of the effective treatment of described individual administration.

In another embodiment, the invention provides a kind of treatment and suffer from the method for xeropthalmus in the individuality of xeropthalmus, it may further comprise the steps: SARM compound and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination of effectively treating one of the formula I-VI of the amount of xeropthalmus in this individuality to described individual administration.

In another embodiment, the invention provides a kind of method of preventing xeropthalmus in the individuality, it may further comprise the steps: SARM compound and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination of effectively preventing one of the formula I-VI of the amount of xeropthalmus in this individuality to described individual administration.

In another embodiment, the invention provides the method for apoptosis in a kind of inducing cancer cell, it may further comprise the steps: the SARM compound of one of formula I-VI of the amount of the apoptosis in making described cancer cells and effectively causing this cell and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination contact.

The new SARM of the present invention can be used for a) male contraception separately or with the form of pharmaceutical composition; B) the multiple and hormone-related conditions of treatment, for example reduce (ADAM) relevant illness, as fatigue, depression, sexual desire reduction, sexual dysfunction, erective dysfunction, hypogonadism, osteoporosis, alopecia, anaemia, obesity, senile amyotrophy, osteopenia, osteoporosis, benign prostatic hyperplasia, mood and cognitive change and prostate cancer with old male sex's male sex hormone; C) treatment reduces (ADIF) relevant illness with women's male sex hormone, as sexual dysfunction, sexual desire reduction, hypogonadism, senile amyotrophy, osteopenia, osteoporosis, mood and cognitive change, depression, anaemia, alopecia, obesity, endometriosis, mammary cancer, uterus carcinoma and ovarian cancer; D) treat and/or prevent acute and/or chronic wasting disease; E) prevent and/or treat xeropthalmus; F) oral androgenic replacement therapy; G) sickness rate of reduction prostate cancer stops prostate cancer or causes prostate cancer to disappear; And/or h) apoptosis in the inducing cancer cell.

SARM compound of the present invention provides the marked improvement for the treatment of steroid male sex hormone.Several SARM compounds of the present invention have the short male and anabolic activity of on-steroidal part to androgen receptor.Other SARM compound of the present invention has the androgen antagonist activity of unexpected on-steroidal part to androgen receptor.Therefore, severe side effect, inconvenient administering mode or expensive will not be followed in the treatment of carrying out with SARM compound of the present invention, and still have oral administration biaavailability, not with other generation cross reaction of steroid acceptor and the advantage of growth transformation period.

Embodiment

Wherein

X is a key, O, CH ₂, NH, Se, PR, NO or NR;

G is O or S;

R ₁Be CH ₃, CH ₂F, CHF ₂, CF ₃, CH ₂CH ₃, or CF ₂CF ₃

T be OH, OR ,-NHCOCH ₃, or NHCOR;

A is selected from following ring:

With

B is selected from following ring:

With

Wherein A and B can not be phenyl ring simultaneously;

Z is NO ₂, CN, COOH, COR, NHCOR or CONHR;

Y is CF ₃, F, I, Br, Cl, CNCR ₃Or SnR ₃

W ₁Be O, NH, NR, NO or S; And

W ₂Be N or NO.

In one embodiment, the invention provides the analogue of formula I compound.In another embodiment, the invention provides the isomer of formula I compound.In another embodiment, the invention provides the metabolite of formula I compound.In another embodiment, the invention provides the derivative of formula I compound.In another embodiment, the invention provides the pharmacologically acceptable salts of formula I compound.In another embodiment, the invention provides the medicine of formula I compound.In another embodiment, the invention provides the hydrate of formula I compound.In another embodiment, the invention provides the N-oxide compound of formula I compound.In another embodiment, the invention provides the impurity of formula I compound.In another embodiment, the invention provides the prodrug of formula I compound.In another embodiment, the invention provides the polymorph of formula I compound.In another embodiment, the invention provides the crystal of formula I compound.In another embodiment, the invention provides analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, impurity, prodrug, polymorph or the crystalline arbitrary combination of formula I compound.

In one embodiment, the invention provides wherein, X is the SARM compound of the formula I of O.

In one embodiment, the invention provides wherein, G is the SARM compound of the formula I of O. exists

In another embodiment, the invention provides wherein, T is the SARM compound of the formula I of OH.

In another embodiment, the invention provides wherein R ₁Be CH ₃The SARM compound of formula I.

In another embodiment, the invention provides wherein, Z is NO ₂The SARM compound of formula I.

In another embodiment, the invention provides wherein, Z is the SARM compound of the formula I of CN.

In another embodiment, the invention provides wherein, Y is CF ₃The SARM compound of formula I.

In another embodiment, the invention provides wherein Q ₁Be NHCOCH ₃The SARM compound of formula I.In another embodiment, the invention provides wherein Q ₁It is the SARM compound of the formula I of F.

Wherein A and B such as above-mentioned Compound I define.

Substituting group Z and Y can be on the optional positions of carrying these substituent rings (hereinafter referred to as " A ring ").In one embodiment, substituting group Z is in the contraposition of A ring.In another embodiment, substituting group Y position between the A ring.In another embodiment, substituting group Z is in the contraposition of A ring, and substituting group Y position between the A ring.

In one embodiment, the A ring shows with following structural table:

In another embodiment, the A ring shows with following structural table:

In another embodiment, the A ring shows with following structural table:

Or

Substituting group Q ₁And Q ₂Can be on the optional position of carrying these substituent rings (hereinafter referred to as " B ring ").In one embodiment, substituting group Q ₁Contraposition at the B ring.In another embodiment, substituting group Q ₂Be hydrogen.In another embodiment, substituting group Q ₁In the contraposition of B ring, and substituting group Q ₂Be hydrogen.In another embodiment, substituting group Q ₁Be NHCOCH ₃And in the contraposition of B ring, and substituting group Q ₂Be hydrogen.

In one embodiment, the B ring shows with following structural table:

In another embodiment, the B ring shows with following structural table:

In another embodiment, the B ring shows with following structural table:

In another embodiment, the B ring shows with following structural table:

Or

In one embodiment, the A ring is represented with one of following heterocycle:

Or

In one embodiment, the B ring is represented with one of following heterocycle:

Or

In one embodiment, the Q on the B ring ₁And/or Q ₂Represent with one of following heterocycle:

In these 5 yuan of heterocycles, W ₁Be O, NH, NR, NO or S; And W ₂Be N or NO.These heterocycles comprise multiple heterocycle, and its nonrestrictive example is pyrroles, imidazoles, furans, thiophene, thiazole, oxazole etc.In addition, annular atoms W wherein ₁And/or W ₂One of to represent the heterocycle of nitrogen can be the form of its corresponding N-oxide compound (NO).

Following examples have illustrated some nonrestrictive example of the SARM compound within the scope of the invention.In one embodiment, SARM compound of the present invention is represented in order to the structure of Formula Il:

Wherein

X is a key, O, CH ₂, NH, Se, PR, NO or NR;

G is O or S;

R ₁Be CH ₃, CH ₂F, CHF ₂, CF ₃, CH ₂CH ₃, or CF ₂CF ₃

T be OH, OR ,-NHCOCH ₃, or NHCOR,

B is selected from following ring:

With

Z is NO ₂, CN, COOH, COR, NHCOR or CONHR;

Y is CF ₃, F, I, Br, Cl, CNCR ₃Or SnR ₃

W ₁Be O, NH, NR, NO or S; And

W ₂Be N or NO.

In one embodiment, the invention provides the analogue of formula II compound.In another embodiment, the invention provides the isomer of formula II compound.In another embodiment, the invention provides the metabolite of formula II compound.In another embodiment, the invention provides the derivative of formula II compound.In another embodiment, the invention provides the pharmacologically acceptable salts of formula II compound.In another embodiment, the invention provides the medicine of formula II compound.In another embodiment, the invention provides the hydrate of formula II compound.In another embodiment, the invention provides the N-oxide compound of formula II compound.In another embodiment, the invention provides the impurity of formula II compound.In another embodiment, the invention provides the prodrug of formula II compound.In another embodiment, the invention provides the polymorph of formula II compound.In another embodiment, the invention provides the crystal of formula II compound.In another embodiment, the invention provides analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, impurity, prodrug, polymorph or the crystalline arbitrary combination of formula II compound.

In one embodiment, the invention provides wherein, X is the SARM compound of the formula II of O.In one embodiment, the invention provides wherein, G is the SARM compound of the formula II of O.In another embodiment, the invention provides wherein, T is the SARM compound of the formula II of OH.In another embodiment, the invention provides wherein R ₁Be CH ₃The SARM compound of formula II.In another embodiment, the invention provides wherein, Z is NO ₂The SARM compound of formula II.In another embodiment, the invention provides wherein, Z is the SARM compound of the formula II of CN.In another embodiment, the invention provides wherein, Y is CF ₃The SARM compound of formula II.In another embodiment, the invention provides wherein Q ₁Be NHCOCH ₃The SARM compound of formula II.In another embodiment, the invention provides wherein Q ₁It is the SARM compound of the formula II of F.

In one embodiment, the invention provides the analogue of formula III compound.In another embodiment, the invention provides the isomer of formula III compound.In another embodiment, the invention provides the metabolite of formula III compound.In another embodiment, the invention provides the derivative of formula III compound.In another embodiment, the invention provides the pharmacologically acceptable salts of formula III compound.In another embodiment, the invention provides the medicine of formula III compound.In another embodiment, the invention provides the hydrate of formula III compound.In another embodiment, the invention provides the N-oxide compound of formula III compound.In another embodiment, the invention provides the impurity of formula III compound.In another embodiment, the invention provides the prodrug of formula III compound.In another embodiment, the invention provides the polymorph of formula III compound.In another embodiment, the invention provides the crystal of formula III compound.In another embodiment, the invention provides analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, impurity, prodrug, polymorph or the crystalline arbitrary combination of formula III compound.

In one embodiment, the invention provides the analogue of formula IV compound.In another embodiment, the invention provides the isomer of formula IV compound.In another embodiment, the invention provides the metabolite of formula IV compound.In another embodiment, the invention provides the derivative of formula IV compound.In another embodiment, the invention provides the pharmacologically acceptable salts of formula IV compound.In another embodiment, the invention provides the medicine of formula IV compound.In another embodiment, the invention provides the hydrate of formula IV compound.In another embodiment, the invention provides the N-oxide compound of formula IV compound.In another embodiment, the invention provides the impurity of formula IV compound.In another embodiment, the invention provides the prodrug of formula IV compound.In another embodiment, the invention provides the polymorph of formula IV compound.In another embodiment, the invention provides the crystal of formula IV compound.In another embodiment, the invention provides analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, impurity, prodrug, polymorph or the crystalline arbitrary combination of formula IV compound.

In another embodiment, the SARM compound is represented by following structure:

Or

In another embodiment, the SARM compound is represented by following structure:

In another embodiment, the SARM compound is represented by following structure:

Wherein

X is a key, O, CH ₂, NH, Se, PR, NO or NR;

G is O or S;

R ₁Be CH ₃, CH ₂F, CHF ₂, CF ₃, CH ₂CH ₃, or CF ₂CF ₃

T be OH, OR ,-NHCOCH ₃, or NHCOR;

A is selected from following ring:

With

Z is NO ₂, CN, COOH, COR, NHCOR or CONHR;

Y is CF ₃, F, I, Br, Cl, CNCR ₃Or SnR ₃

W ₁Be O, NH, NR, NO or S; And

W ₂Be N or NO.

In one embodiment, the invention provides the analogue of formula V compound.In another embodiment, the invention provides the isomer of formula V compound.In another embodiment, the invention provides the metabolite of formula V compound.In another embodiment, the invention provides the derivative of formula V compound.In another embodiment, the invention provides the pharmacologically acceptable salts of formula V compound.In another embodiment, the invention provides the medicine of formula V compound.In another embodiment, the invention provides the hydrate of formula V compound.In another embodiment, the invention provides the N-oxide compound of formula V compound.In another embodiment, the invention provides the impurity of formula V compound.In another embodiment, the invention provides the prodrug of formula V compound.In another embodiment, the invention provides the polymorph of formula V compound.In another embodiment, the invention provides the crystal of formula V compound.In another embodiment, the invention provides analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, impurity, prodrug, polymorph or the crystalline arbitrary combination of formula V compound.

The invention provides wherein, X is the SARM compound of the formula V of O.In one embodiment, the invention provides wherein, G is the SARM compound of the formula V of O.In another embodiment, the invention provides wherein, T is the SARM compound of the formula V of OH.In another embodiment, the invention provides wherein R ₁Be CH ₃The SARM compound of formula V.In another embodiment, the invention provides wherein, Z is NO ₂The SARM compound of formula V.In another embodiment, the invention provides wherein, Z is the SARM compound of the formula V of CN.In another embodiment, the invention provides wherein, Y is CF ₃The SARM compound of formula V.In another embodiment, the invention provides wherein Q ₁Be NHCOCH ₃The SARM compound of formula V.In another embodiment, the invention provides wherein Q ₁It is the SARM compound of the formula V of F.

In one embodiment, the invention provides the analogue of formula VI compound.In another embodiment, the invention provides the isomer of formula VI compound.In another embodiment, the invention provides the metabolite of formula VI compound.In another embodiment, the invention provides the derivative of formula VI compound.In another embodiment, the invention provides the pharmacologically acceptable salts of formula VI compound.In another embodiment, the invention provides the medicine of formula VI compound.In another embodiment, the invention provides the hydrate of formula VI compound.In another embodiment, the invention provides the N-oxide compound of formula VI compound.In another embodiment, the invention provides the impurity of formula VI compound.In another embodiment, the invention provides the prodrug of formula VI compound.In another embodiment, the invention provides the polymorph of formula VI compound.In another embodiment, the invention provides the crystal of formula VI compound.In another embodiment, the invention provides analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, impurity, prodrug, polymorph or the crystalline arbitrary combination of formula VI compound.

In another embodiment, the SARM compound is represented by following structure:

Or

In another embodiment, the SARM compound is represented by following structure:

In another embodiment, the SARM compound is represented by following structure:

In another embodiment, the SARM compound is represented by following structure:

Or

In another embodiment, the SARM compound is represented by following structure:

Or

In another embodiment, the SARM compound is represented by following structure:

Or

In another embodiment, the SARM compound is represented by following structure:

Or

Definition

Substituent R is defined herein as alkyl, haloalkyl, dihalo alkyl, tri haloalkyl, CH ₂F, CHF ₂, CF ₃, CF ₂CF ₃, aryl, phenyl, F, Cl, Br, I, thiazolinyl or hydroxyl (OH).

" alkyl " group is meant aliphatic saturated hydrocarbon, comprises straight chained alkyl, branched-chain alkyl and cycloalkyl.In one embodiment, alkyl has 1-12 carbon.In another embodiment, alkyl has 1-7 carbon.In another embodiment, alkyl has 1-6 carbon.In another embodiment, alkyl has 1-4 carbon.Alkyl can not be substituted or is selected from following group and replaces by one or more: halogen, hydroxyl, carbalkoxy, amido, alkyl amido, dialkyl group amido, nitro, amino, alkylamino, dialkyl amido, carboxyl, sulfo-and alkylthio.

" haloalkyl " is meant by the alkyl of the above definition of one or more halogen atoms such as F, Cl, Br or I replacement.Halogen is meant the element in the periodic table of elements VII family, for example F, Cl, Br or I.

" aryl " is meant the aromatic group with at least one carbocyclic ring aromatic group or heteroaromatic group, and it can not be substituted or is selected from following group and replaces by one or more: halogen, haloalkyl, hydroxyl, carbalkoxy, amido, alkyl amido, dialkyl group amido, nitro, amino, alkylamino, dialkyl amido, carboxyl or sulfo-or alkylthio.The limiting examples of aromatic ring is phenyl, naphthyl, pyranyl, pyrryl, pyrazinyl, pyrimidyl, pyrazolyl, pyridyl, furyl, thiophenyl, thiazolyl, imidazolyl, isoxazolyl etc.

" hydroxyl " group refers to the OH group." thiazolinyl " group refers to have the group of the two keys of at least one carbon one carbon.

" arylalkyl " group refers to the alkyl that is connected with aryl, wherein alkyl and aryl such as above definition.The example of arylalkyl is a benzyl.

Consider as this paper, the present invention relates to the application of SARM compound and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their combination.In one embodiment, the present invention relates to the application of the analogue of SARM compound.In another embodiment, the present invention relates to the application of the derivative of SARM compound.In another embodiment, the present invention relates to the application of the isomer of SARM compound.In another embodiment, the present invention relates to the application of the metabolite of SARM compound.In another embodiment, the present invention relates to the application of the pharmacologically acceptable salts of SARM compound.In another embodiment, the present invention relates to the application of the medicine of SARM compound.In another embodiment, the present invention relates to the application of the hydrate of SARM compound.In another embodiment, the present invention relates to the application of the N-oxide compound of SARM compound.In another embodiment, the present invention relates to the application of the prodrug of SARM compound.In another embodiment, the present invention relates to the application of the polymorph of SARM compound.In another embodiment, the present invention relates to the application of the crystal thing of SARM compound.In another embodiment, the present invention relates to the application of analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or the crystalline arbitrary combination of SARM compound of the present invention.

As defined herein, term " isomer " includes but not limited to optical isomer and analogue, constitutional isomer and analogue, conformer and analogue etc.

In one embodiment, the present invention includes the application of the different optical isomer of SARM compound.Those skilled in the art will recognize that SARM compound of the present invention contains at least one chiral centre.Therefore, be used for the SARM compound of the inventive method can optical activity or racemic form exist or separate.Some compounds can also show polymorphism.Should be appreciated that, the present invention includes any racemize, optical activity, polymorphic form or stereoisomeric forms in any ratio or their mixture, these forms have the character that is used for the treatment of the illness relevant with male sex hormone as herein described.In one embodiment, the SARM compound is pure (R)-isomer.In another embodiment, the SARM compound is pure (S)-isomer.In another embodiment, the SARM compound is (R) and (S) mixture of isomers.In another embodiment, the SARM compound is to comprise the equivalent (R) and (S) racemic mixture of isomer.The known optical activity form (for example,,, synthesizing) that how to prepare in this area perhaps by using chiral stationary phase to carry out chromatographic separation by chirality by synthetic by the optical activity raw material by recrystallization technology resolution of racemic form.

The present invention includes amino-substituted compounds and pharmacologically acceptable salts organic and mineral acid such as citric acid and hydrochloric acid.The present invention also comprises the amino substituent N-oxide compound of compound as herein described.Pharmacologically acceptable salts can also be by using mineral alkali such as sodium-hydroxide treatment phenolic compound from its preparation.And, can prepare the ester of phenolic compound with fat and aromatic carboxylic acid such as acetate and benzoic ether.

The present invention also comprises the derivative of SARM compound.Term " derivative " includes but not limited to ether derivant, acid derivative, amide derivatives, ester derivative etc.In addition, the present invention also comprises the hydrate of SARM compound.Term " hydrate " includes but not limited to semihydrate, monohydrate, dihydrate, trihydrate etc.

The present invention also comprises the metabolite of SARM compound.Term " metabolite " is meant any material that is produced by metabolism or metabolic process by another kind of material.

The present invention also comprises the medicine of SARM compound.Term " medicine " is meant and is suitable for medicinal composition (pharmaceutical composition), as defined herein.

The present invention also comprises the prodrug of SARM compound.Term " prodrug " be meant by such as hydrolysis, esterification, take off reactions such as esterification, activation, salify and can be converted into the material of biologically active agent in vivo.

The present invention also comprises the crystal of SARM compound.The present invention also comprises the polymorphic form of SARM compound.Term " crystal " is meant the material of crystal habit.Term " polymorphic form " is meant a kind of material of characteristic crystal form, and it has the physical properties of feature such as X-ray diffraction, IR spectrum, fusing point etc.

The biological activity of selective androgen conditioning agent compound

SARM (SARM) compound is a new class androgen receptor target agent, and they can be used for a) male contraception as mentioned above; B) the multiple and hormone-related conditions of treatment, for example reduce (ADAM) relevant illness, as fatigue, depression, sexual desire reduction, sexual dysfunction, erective dysfunction, hypogonadism, osteoporosis, alopecia, anaemia, obesity, senile amyotrophy, osteopenia, osteoporosis, benign prostatic hyperplasia, mood and cognitive change and prostate cancer with old male sex's male sex hormone; C) treatment reduces (ADIF) relevant illness with women's male sex hormone, as sexual dysfunction, sexual desire reduction, hypogonadism, senile amyotrophy, osteopenia, osteoporosis, mood and cognitive change, depression, anaemia, alopecia, obesity, endometriosis, mammary cancer, uterus carcinoma and ovarian cancer; D) treat and/or prevent acute and/or chronic wasting disease; E) prevent and/or treat xeropthalmus; F) oral androgenic replacement therapy; G) sickness rate of reduction prostate cancer stops prostate cancer or causes prostate cancer to disappear; And/or h) apoptosis in the inducing cancer cell.

As used herein, extracellular signaling molecule acceptor is referred to as " cell signal acceptor ".Many cell signal acceptors are the transmembrane proteins on the cell surface; When they during in conjunction with extracellular signaling molecule (being part), their activate to produce signal cascade in the cell that changes cell behavior.On the contrary, in some cases, acceptor is in cell, and the signal part must enter cell and activates them; Therefore these signaling molecules must be enough little and hydrophobic, to diffuse through the plasma membrane of cell.

Steroid hormone is an example of little hydrophobic molecule, and it directly diffuses through the plasma membrane of target cell and combines with the cell within a cell frizzled receptor.These acceptors are structurally relevant, and constitute intracellular receptor superfamily (or steroid hormone receptor superfamily).Steroid hormone receptor comprises PgR, estrogen receptor, androgen receptor, glucocorticoid receptor and mineralocorticoid acceptor.The present invention relates to androgen receptor especially.

Except part and receptors bind, can be with receptor blocking to stop the part combination.When material and receptors bind, the three-dimensional structure of material is with the suitable space that is formed by the acceptor three-dimensional structure of the configuration of ball and groove.Ball and groove are fit to well more, and its maintenance is tight more.This phenomenon is called avidity.If the avidity of material is greater than the primary hormone, it will and combine with combining site more continually with the hormone competition.In case combination, signal can be sent in the cell by acceptor, causes cell to be replied in some way.This is called activation.In case activate, then the activated acceptor is directly regulated transcribing of specific gene.But this material and acceptor may have some attribute except that avidity, with activating cells.Chemical bond between the atom of material and the atom of acceptor may form.In some cases, this causes the acceptor configuration to change, thereby is enough to start activation process (being called signal transduction).

In one embodiment, the present invention relates to SARM compound as agonist compound.Receptor stimulant is with receptors bind and with its activated material.Therefore, in one embodiment, SARM compound of the present invention is used for the steroid hormone receptors bind and activates it.In one embodiment, agonist compound of the present invention is and androgen receptor bonded agonist.In another embodiment, this compound has high affinity to androgen receptor.In another embodiment, this agonist compound also has anabolic activity.In another embodiment, the invention provides androgen receptor is had the excitement of non-steroids and the selective androgen conditioning agent compound of anabolic activity.

In another embodiment, the present invention relates to SARM compound as agonist compounds.Receptor antagonist is with receptors bind and makes the material of its inactivation.Therefore, in one embodiment, SARM compound of the present invention is used for combining and making with steroid hormone receptor its inactivation.In one embodiment, agonist compounds of the present invention is and androgen receptor bonded antagonist.In another embodiment, this compound has high affinity to androgen receptor.

In another embodiment, SARM compound of the present invention can be classified as part A R agonist/antagonist.The SARM compound is the AR agonist in some tissue, causes the AR-reactive group to transcribe increase (for example muscle anabolic action).In other tissue, these compounds are as the AR inhibitor, to stop natural androgenic agonism.

Determine that compound of the present invention is that the AR agonist or the assay method of antagonist are known for a person skilled in the art.For example, the AR agonist activity can keep and/or stimulates the ability of the growth of the tissue that contains AR such as prostate gland and seminal vesicle to determine by adopting weight determination to monitor the SARM compound.The AR antagonistic activity can be determined by the ability that monitoring SARM compound suppresses to contain the growth of AR tissue.

Compound of the present invention is reversible or irreversibly combine with androgen receptor.In one embodiment, androgen receptor is mammiferous androgen receptor.In another embodiment, androgen receptor is people's a androgen receptor.In one embodiment, SARM compound of the present invention reversibly with Mammals, for example people's androgen receptor combination.Compound is meant that with the reversible combination of acceptor compound can separate from acceptor after combination.

In another embodiment, the SARM compound irreversibly combines with the androgen receptor of Mammals (for example people).Therefore, in one embodiment, compound of the present invention can contain the functional group (for example avidity marker) of permission with androgen receptor alkylation (being that covalent linkage forms).Therefore, in this case, this compound is the alkylating agent with the acceptor irreversible fixation, thereby can not be replaced as endogenic ligand DHT and testosterone by steroid." alkylating agent " is defined as in this article with cellular component, as the reagent of DNA, RNA or enzyme alkylation (formation covalent linkage).It is a kind of highly active chemical substance, and it introduces bioactive molecules with alkyl, thereby stops their correct functions.Alkylation partly be with cellular component in the interactional electrophilic group of nucleophilic part.

According to one embodiment of the invention, provide by making acceptor and SARM compound and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination cause contacting SARM compound of the present invention and the androgen receptor bonded method of making under SARM compound and the androgen receptor bonded condition effectively.The bound energy of SARM compound and androgen receptor makes compound of the present invention be used as male contraceptive pill and is used for many hormonotherapies.Agonist compound combines with androgen receptor and with its activation.Agonist compounds combines and makes its inactivation with androgen receptor.The combination of agonist or agonist compounds is reversible or irreversible.

According to another embodiment of the invention, provide by making individual androgen receptor and making SARM compound and androgen receptor combination effectively and suppress the SARM compound of the present invention of spermatogenetic amount and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination contact and suppress individual spermatogenetic method.

According to another embodiment of the invention, provide to make the male individual method of contraception, its may further comprise the steps: thereby effectively suppress SARM compound of the present invention and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination that this individuality sperm produces the amount that causes this individuality contraception to this individuality administration.

According to another embodiment of the invention, the methods of hormonal treatment of patient (promptly suffering from the patient of androgen-dependent illness) is provided, it comprise the androgen receptor that makes the patient with make effectively SARM compound and androgen receptor in conjunction with and change the SARM compound of the present invention of amount of androgen-dependent illness and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination and contact.

According to another embodiment of the invention, patient's hormone replacement therapy method is provided, it comprise the androgen receptor that makes the patient with make effectively SARM compound and androgen receptor in conjunction with and change the SARM compound of the present invention of amount of androgen-dependent illness and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination and contact.

According to another embodiment of the invention, provide treatment to suffer from method with the individuality of hormone-related conditions, it comprises to this individuality administration makes the SARM compound combine with androgen receptor effectively and changes SARM compound of the present invention and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination of the amount of androgen-dependent illness.

The androgen-dependent illness that can treat according to the present invention comprises and old and feeble relevant illness, as hypogonadism, senile amyotrophy, erythropoiesis, osteoporosis and any illness that depends on low male sex hormone (for example testosterone) level that other was determined afterwards.

According to another embodiment, the invention provides a kind of treatment and suffer from the method for the individuality of prostate cancer, it may further comprise the steps SARM compound of the present invention and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination of effectively treating the amount of described individual prostate cancer to described individual administration.

According to another embodiment, the invention provides a kind of method of preventing individual prostate cancer, it may further comprise the steps: SARM compound of the present invention and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination of effectively preventing the amount of described individual prostate cancer to described individual administration.

According to another embodiment, the invention provides the method for prostate cancer development in a kind of individuality that delays to suffer from prostate cancer, it may further comprise the steps: effectively delay SARM compound of the present invention and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination of the amount of prostate cancer development in the described individuality to described individual administration.

According to another embodiment, the invention provides the method for prostate cancer recurrence in a kind of individuality that prevents to suffer from prostate cancer, it may further comprise the steps: effectively prevent SARM compound of the present invention and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination of the amount of prostate cancer recurrence in the described individuality to described individual administration.

According to another embodiment, the invention provides a kind of treatment and suffer from the method for prostate cancer recurrence in the individuality of prostate cancer, it may further comprise the steps: SARM compound of the present invention and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination of the amount of prostate cancer recurrence in the described individuality of the effective treatment of described individual administration.

And the stimulation of androgen receptor promotes tear to produce, and therefore SARM compound of the present invention can be used for the treatment of xeropthalmus.Therefore, according to another embodiment, the invention provides a kind of treatment and suffer from the method for xeropthalmus in the individuality of xeropthalmus, it may further comprise the steps: effectively treat SARM compound of the present invention and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination of the amount of xeropthalmus in this individuality to described individual administration.

According to another embodiment, the invention provides a kind of method of preventing xeropthalmus in the individuality, it may further comprise the steps: effectively prevent SARM compound of the present invention and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination of the amount of xeropthalmus in this individuality to described individual administration.

In another embodiment, the invention provides the method for apoptosis in a kind of inducing cancer cell, it may further comprise the steps: the SARM compound of the present invention of the amount of the apoptosis in making described cancer cells and effectively causing this cell and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination contact.

As defined herein, " contact " is meant in test tube, flask, tissue culture, chip, array, flat board, microplate, kapillary etc. SARM compound introducing of the present invention contained in the sample of enzyme, and be enough to allow incubation under SARM and the enzyme bonded temperature and time.The method that is used to sample is contacted with SARM or other specific binding component is known for a person skilled in the art, and can select according to the type of the mensuration scheme that will carry out.The incubation method also is a standard, and is known for a person skilled in the art.

In another embodiment, term " contact " is meant to be introduced SARM compound of the present invention in the individuality of receiving treatment, and this SARM compound is contacted in vivo with androgen receptor.

As used herein, term " sexual desire " is meant the sexual desire prestige.

As used herein, term " erection " is meant and can erects.Erectile tissue is can significantly enlarge and the tissue of hardening by the expansion of its contained a large amount of blood vessels.

" hypogonadism " is to cause or be the illness of feature with it, growth and sexual development delay by active reduction of unusual gonad function." osteopenia " phalanges calcification or density reduce.This is the term that comprises the Skeletal system of all visible this illnesss.

" osteoporosis " refers to attenuate and the bone amount reduces owing to bone that the forfeiture of calcium and bone protein causes.Osteoporosis makes the people be easy to fracture, and fractures often to cure slowly or be difficult to and cure.Unchecked osteoporosis may cause posture change, body abnormality and handiness to reduce.

" BPH (benign prostatic hyperplasia) " is prostatic non-pernicious increase, and is the modal non-neoplasm sexual abnormality seen in any internal, and is the major cause of adult man morbid state.The BPH sickness rate that age surpasses 50 years old the male sex surpasses 75%, reaches 88% to 80-90 when year sickness rate.BPH causes crossing the slow extruding of prostatic urethra part (prostate-urethra) usually.This causes the patient often to urinate forwardly, because the bladder emptying not exclusively and is in a hurry urinated.The obstruction of urine stream also may cause the general control of urinating that lacks, comprise beginning when wishing difficulty of urinating and the difficulty that stops urine stream because can not be from bladder drained of urine, this illness is called the overflowing property urinary incontinence, it may cause urinary tract obstruction and the failure of urinating.

" cognition " points out the process of knowledge, particularly knows, cognitive, thinking, study and the process judged.Cognitive relevant with psychology, linguistics, computer science, neuroscience, mathematics, study of behaviour and philosophy.Term " mood " refers to the temper or the mental status.The change that this paper considers is meant any positive or passive variation of cognition and/or mood.

The disease of term " depression " reference and health, mood and thought, it influences people's the mode of having a meal, sleeping and feels and for the mode of object thinking.Depressed sign and illness comprise devitalization interest, forfeiture appetite or overfeeding, forfeiture expression, hollow, sensation is desperate, pessimistic, evil or helpless, social withdrawal, fatigue, dyssomnias, attention are concentrated difficulty, memory difficulty or it is difficult, fidgety to determine, irritability, headache, digestive ailment or chronic pain.

Term " alopecia " medically is being called alopecia, refers to that very the android type of common form is bald.The bald sheet that generally starts from the scalp is bald, develop into sometimes bald fully, even the forfeiture chaeta.Alopecia influences masculinity and femininity.

" anaemia " refer to RBC number less than oxyphorase number in normal value or the blood less than the illness of normal value.Therefore the negative oxygen ability of blood reduces.The people who suffers from anaemia may feel tired and tired easily, and appearance is pale, produces palpitaition and becomes short of breath usually.Anaemia is caused by four fundamental factor: a) hemorrhage (bleeding); B) haemolysis (erythrocytic too much destruction); C) red corpuscle produces not enough; And d) no enough Hb A hemoglobin adults.The anaemia that has many forms comprises underdevelopment anaemia, benzolism, fanconi syndrome anaemia, newborn hemolytic disease, hereditary spherocytosis, sideropenic anemia, osteopetrosis, pernicious anemia, sickle cell disease, thalassemia, spinal cord heteroplasia syndrome and multiple bone marrow disease.Consider that as this paper SARM compound of the present invention is used to prevent and/or treat the anaemia of any one or more above-mentioned form.

" obesity " refers to substantially exceed the state of normal type.Usually, if a people exceeds 20% than its ideal body weight, then think his obesity.It is 30 or bigger that National Institute of Health (NIH) accurately is defined as obesity body-mass index (BMI).Obesity often is multifactorial, based on heredity and behavial factor.The overweight health problem that obviously causes that causes by obesity.It increases the risk that generation comprises following multiple disease: II type (adult onset) diabetes; Hypertension; Apoplexy (cerebrovascular accident or CVA); Heart attack (myocardial infarction or MI); Heart failure (congestive heart failure); Cancer (some form such as prostate cancer and colon and the rectum cancer); Cholelithiasis and gallbladder disease (cholecystitis); Gout and urarthritis; The osteoarthritis of knee, hip and lower back (degenerative arthritis); Sleep apnea (can not eupnea between sleep period, blood oxygen reduces); And pickwickian syndrome (fat, flushing, hypoventilation and sleepiness).Consider that as this paper term " obesity " comprises any above-mentioned with fat relevant illness and disease.Therefore, SARM compound of the present invention is used to prevent and/or treat obesity and any one or more above-mentioned with fat relevant illness and disease.

" prostate cancer " is one of the most normal cancer that betides the U.S. male sex, diagnoses out hundreds thousand of new cases every year.Have in the cases for prostate cancer of new diagnosis that discovery is to develop on the pathology 60% or more, can't cure and prognosis not good.1/3 prostate cancer of suffering from potential form is arranged among the male sex more than 50 years old, and it may be activated into life-threatening clinical prostate cancer form.Between the fifties to the nineties, the occurrence frequency of potential tumor of prostate all significantly increased in per ten years, and be 5.3-14% the fifties, and be 40-80% the nineties.People's the number of suffering from potential prostate cancer is identical between literate, the ethnic group of institute and race, yet the occurrence frequency of clinical aggressive cancer is significantly different.This shows that environmental factors may work in activating potential prostate cancer.

Pharmaceutical composition

In one embodiment, methods of treatment of the present invention comprises that administration comprises SARM compound of the present invention and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination, and the pharmaceutical composition of pharmacology acceptable carrier.

As used herein, term " pharmaceutical composition " is meant the activeconstituents (SARM compound of the present invention promptly) that comprises " significant quantity " and the composition of pharmacology acceptable carrier or thinner.

As used herein, term " significant quantity " is meant the amount that result of treatment is provided for illness of determining and medication." significant quantity " of SARM compound of the present invention can be in 1-500mg/ days scope.In one embodiment, dosage is in 1-100mg/ days scope.In another embodiment, dosage is in 100-500mg/ days scope.In another embodiment, dosage is in 45-60mg/ days scope.In another embodiment, dosage is in 15-25mg/ days scope.In another embodiment, dosage is in 55-65mg/ days scope.In another embodiment, dosage is in 45-60mg/ days scope.The SARM compound can comprise single dosage formulation administration every day of whole per daily dose, but also is divided into a plurality of dosed administrations every day, for example every day secondary or every day three times.The SARM compound is intermittently administration also, for example every other day is administered once, and administration is 3 days weekly, and administration is 4 days weekly, weekly administration 5 days etc.

As used herein, term " treatment " comprises preventative and the treatment of the disease property alleviated.As used herein, the common implication of term " minimizing " and " inhibition " is interpreted as and alleviates or reduce.As used herein, term " helps " common implication and is interpreted as that speed increases.As used herein, the common implication of term " promotion " is interpreted as increase.As used herein, term " development " is that how or severity increase, advance, growth or variation.

As used herein, term " administration " is to instigate individuality to contact with SARM compound of the present invention.As used herein, administration can promptly be finished in test tube external, or in vivo, promptly finishes in live organism such as people's cell or tissue.In one embodiment, the present invention includes to individual administration compound of the present invention.In one embodiment, described individuality is a mammalian subject.In another embodiment, described individuality is the people.

The pharmaceutical composition that comprises the SARM medicine can deliver medicine in the individuality by any means well known by persons skilled in the art, for example parenteral route, cancer side (paracancerally), the administration through mucous membrane, in skin, intramuscular, intravenously, intracutaneous, subcutaneous, intraperitoneal, ventricle, in intravaginal, encephalic and the tumour.

In one embodiment, this pharmaceutical composition is an oral administration, and therefore is formulated as the formulation that is suitable for oral administration, i.e. solid or liquid preparation.Suitable solid oral dosage form comprises tablet, capsule, pill, granule, micro tablet etc.Suitable liquid oral dosage form comprises solution, suspension, dispersion agent, emulsion, finish etc.In one embodiment of the invention, this SARM compound is formulated as capsule formulation.According to this embodiment, composition of the present invention also comprises hard gelatin capsule except that SARM active compound and inert support or thinner.

In addition, in another embodiment, this pharmaceutical composition is by intravenously, intra-arterial or the intramuscular injection administration of liquid preparation.Suitable liquid dosage form comprises solution, suspensoid, dispersion agent, emulsion, finish etc.In one embodiment, this pharmaceutical composition is an intravenous administration, and therefore is formulated as the formulation that is suitable for intravenous administration.In another embodiment, this pharmaceutical composition is the intra-arterial administration, and therefore is formulated as the formulation that is suitable for the intra-arterial administration.In another embodiment, this pharmaceutical composition is the intramuscular administration, and therefore is formulated as the formulation that is suitable for the intramuscular administration.

In addition, in another embodiment, this pharmaceutical composition is the body surface topical, and therefore is formulated as the formulation that is suitable for topical.Suitable topical dosage forms comprises gelifying agent, ointment, emulsifiable paste, washing lotion, drops etc.For topical, derivative that can tolerate on this SARM medicine or its physiology such as salt, ester class, N-are oxide-based etc. can contain or not contain the form preparation of solution, suspension or emulsion in the pharmacology acceptable diluent of medicine carrier and use.

In addition, in another embodiment, this pharmaceutical composition is with the suppository administration, as rectal suppository or urethral suppositories.In addition, in another embodiment, this pharmaceutical composition is by the administration of subdermal implantation micro tablet.In another embodiment, this micro tablet can be at one section long time controlled release SARM medicine.

In another embodiment, this active compound can transmit in capsule, especially in liposome (referring to Langer, Science 249:1527-1533 (1990); Treat etc., in Liposomes in theTherapy of Infectious Disease and Cancer, Lopez-Berestein and Filder (eds.), Liss, New York, pp.353-365 (1989); Lopez-Berestein, ibid., pp.317-327; Ibid).

" pharmacology acceptable carrier and thinner " that the present invention uses is well known to those skilled in the art.This carrier or thinner can be solid carrier or thinner, liquid dosage form be can be liquid vehicle or thinner solid dosage, or their mixture.

Solid carrier/thinner includes but not limited to natural gum, starch (as W-Gum, pregelatinized Starch), sugar (as lactose, N.F,USP MANNITOL, sucrose, glucose), cellulose materials (as Microcrystalline Cellulose), acrylate (as polymethacrylate), lime carbonate, magnesium oxide, talcum or their mixture.

For liquid dosage form, the pharmacology acceptable carrier can be the aqueous solution or non-aqueous solution, suspension, emulsion or finish.Examples of non-aqueous is propylene glycol, polyoxyethylene glycol and injectable organic ester such as ethyl oleate.Aqueous carrier comprises water, ethanol/water solution, emulsion or suspension, comprises salt solution and buffering medium.The example of oil is oil, animal oil, vegetables oil or synthetic oil, as peanut oil, soybean oil, mineral oil, sweet oil, Trisun Oil R 80 and Oils,glyceridic,cod-liver.

The outer carrier (with regard to subcutaneous, intravenously, intra-arterial or intramuscular injection) of gi tract comprises sodium chloride solution, woods Ge Shi glucose, glucose and sodium-chlor, lactic acid woods Ge Shi and fixed oil.Intravenous vehicles comprises that fluid and nutritious supplementary, electrolyte replenisher such as those are based on carrier of woods Ge Shi glucose etc.Example is to contain or do not contain sterile liquid Ru Shui and the oil that tensio-active agent and other drug are learned acceptable adjuvant.Usually, water, salt solution, dextrose hydrate and relevant sugar soln, and glycols such as propylene glycol or polyoxyethylene glycol be preferred liquid vehicle, especially with regard to Injectable solution.The example of oil is oil, animal oil, vegetables oil or synthetic oil, as peanut oil, soybean oil, mineral oil, sweet oil, Trisun Oil R 80 and Oils,glyceridic,cod-liver.

In addition, said composition can comprise that also tackiness agent is (as gum arabic, W-Gum, gelatin, carbomer, ethyl cellulose, guar gum, hydroxypropylcellulose, Vltra tears, polyvidone), disintegrating agent is (as W-Gum, yam starch, Lalgine, silicon-dioxide, cross-linked carboxymethyl cellulose sodium, polyvinylpolypyrrolidone, guar gum, carboxymethylstach sodium), the damping fluid of different PH and ionic strength is (as Tris-HCl, acetate, phosphoric acid salt), additive is as preventing to be adsorbed to the albumin or the gelatin on surface, sanitising agent is (as polysorbas20, tween 80, Pluronic F68, cholate), proteinase inhibitor, tensio-active agent (as Sodium Lauryl Sulphate BP/USP), penetration enhancer, solubilizing agent (as: glycerine, polyoxyethylene glycol), antioxidant is (as vitamins C, Sodium Pyrosulfite, Butylated Hydroxyanisole), stablizer is (as hydroxypropylcellulose, Vltra tears), thickening material is (as carbomer, colloidal silica, ethyl cellulose, guar gum), sweeting agent is (as aspartame, citric acid), sanitas is (as Thiomersalate, phenylcarbinol, parabens), lubricant is (as stearic acid, Magnesium Stearate, polyoxyethylene glycol, Sodium Lauryl Sulphate BP/USP), glidant (as colloidal silica), softening agent is (as diethyl phthalate, triethyl citrate), emulsifying agent is (as carbomer, hydroxypropylcellulose, Sodium Lauryl Sulphate BP/USP), polymeric coatings material (as poloxamer or poloxamines), dressing and film forming material are (as ethyl cellulose, acrylate, polymethacrylate) and/or adjuvant.

In one embodiment, pharmaceutical composition provided herein is a controlled release composition, i.e. the composition that discharges during the certain hour section after the administration of SARM compound wherein.Controlled release or slow releasing composition comprise the formulation in the lipotropy bank (as lipid acid, wax class, oils).In another embodiment, said composition is an immediate release composition, i.e. the composition that discharges immediately after administration of all SARM compounds wherein.

In another embodiment, this pharmaceutical composition can transmit in controlled release system.For example, this medicine can venoclysis, implantable osmotic pump, percutaneous plaster, liposome or other administering mode administration.In one embodiment, can use pump (referring to Langer, supra; Sefton, CRC Crit.Ref.Biomed.Eng.14:201 (1987); Buchwald etc., Surgery 88:507 (1980); Saudek etc., N.Engl.J.Med.321:574 (1989)).In another embodiment, can use polymeric material.In another embodiment, this controlled release system can be placed, just so only need the part body dose (referring to as Goodson near administration target place such as brain, in Medical Applications of ControlledRelease, supra, vol.2, pp.115-138 (1984)).Langer has discussed other controlled release system (Science 249:1527-1533 (1990)) in summary.

Said composition also can comprise active substance is attached among the granular preparation of polymkeric substance such as poly(lactic acid), polyglycolic acid, hydrogel etc. or on, or be attached on liposome, micro emulsion, micelle, single or multiple lift capsule, blood shadow or the spheroplast.Said composition can influence rate of release and the interior clearance rate of body in physical condition, solubleness, stability, the body.

The present invention also comprises with polymkeric substance (as poloxamer or poloxamines) coated granules composition, and is attached to antibody with antagonism tissue specificity acceptor, part or antigenic compound or be attached to compound on the part of tissue specificity acceptor.

The present invention also comprises by the compound with multipolymer, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone or the modification of polyproline covalent attachment of water-soluble polymers such as polyoxyethylene glycol, polyoxyethylene glycol and polypropylene glycol.Known this modified compound through the transformation period in blood after the intravenous injection significantly greater than transformation period (Abuchowski etc., 1981, Newmark etc., 1982 of corresponding unmodified compound; And Katre etc., 1987).This modification also can increase the solubleness of compound in the aqueous solution, immunogenicity and the reactivity of eliminating clustering phenomena, physics that improves this compound and chemical stability and significantly reducing this compound.As a result, can be by the affixture of this polymkeric substance-compound be reached biological activity in the required body with the frequency of the compound that is lower than unmodified or dosed administration.

The preparation of drug combination that comprises activeconstituents is known in the art, for example can be by mixing, granulate or becoming blade technolgy.This active treatment composition often can accept with pharmacology and the vehicle compatible with activeconstituents mixes mutually.For oral administration, derivative that can tolerate on this SARM medicine or its physiology such as salt, ester, N-oxide compound etc. mix mutually with additive such as vehicle, stablizer or inert diluent that oral administration is habitually practised, and the method by routine is converted into the formulation that is suitable for administration such as tablet, coated tablet, hard or soft gelatin capsule, water, alcohol or oil solution.For the gi tract external administration, derivative that can tolerate on this SARM medicine or its physiology such as salt, ester, N-oxide compound etc. can together be converted into solution, suspensoid or emulsion with material of habitually practising and suiting such as solubilizing agent etc. herein when needed.

Activeconstituents can be mixed with the composition through the acceptable salt form of neutral pharmacology.The acceptable salt of pharmacology comprises and adds sour salify: (forming with the free amine group of polypeptide or antibody molecule), this salt be by mineral acid example hydrochloric acid or phosphoric acid, or formation such as organic acid such as acetic acid, oxalic acid, tartrate, amygdalic acid.The salt that is formed by free carboxy also can be derived by mineral alkali such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide or ironic hydroxide and organic bases such as Isopropylamine, Trimethylamine 99,2-ethamine ethanol, Histidine, PROCAINE HCL, PHARMA GRADE etc. and be formed.

For medicinal use, the salt of this SARM compound is the acceptable salt of pharmacology.Yet other salt also can be used for the preparation of The compounds of this invention or the acceptable salt of its pharmacology.The suitable acceptable salt of pharmacology of The compounds of this invention comprises and adds sour salify that it can be by mixing the solution of The compounds of this invention and the solution of the acceptable acid of pharmacology.The acceptable acid of this pharmacology for example can be hydrochloric acid, sulfuric acid, methylsulfonic acid, fumaric acid, toxilic acid, succsinic acid, acetate, phenylformic acid, oxalic acid, citric acid, tartrate, carbonic acid or phosphoric acid.

In one embodiment, method of the present invention comprises the SARM compound as single effective constituent administration.Yet scope of the present invention also contains following method: a) male contraception; B) the multiple and hormone-related conditions of treatment for example reduces (ADAM) relevant illness with old male sex's male sex hormone; C) treatment reduces (ADIF) relevant illness with women's male sex hormone; D) treat and/or prevent acute and/or chronic wasting disease; E) prevent and/or treat xeropthalmus; F) oral androgenic replacement therapy; G) sickness rate of reduction prostate cancer stops prostate cancer or causes prostate cancer to disappear; And/or h) apoptosis in the inducing cancer cell, it comprises this SARM compound of Combined Preparation and one or more kind medicines.These medicines are including, but not limited to LHRH analogue, reversibility antiandrogen, estrogen antagonist material, anticarcinogen, 5-alpha reductase inhibitor, aromatase inhibitor, progesterone or the medicine that works by other nuclear hormone receptor.

Therefore, in one embodiment, the invention provides the combination and the pharmaceutical composition that comprise SARM compound and LHRH analogue.In another embodiment, the invention provides combination and the pharmaceutical composition that comprises SARM compound and reversibility antiandrogen.In another embodiment, the invention provides combination and the pharmaceutical composition that comprises SARM compound and estrogen antagonist material.In another embodiment, the invention provides combination and the pharmaceutical composition that comprises SARM compound and anticarcinogen.In another embodiment, the invention provides combination and the pharmaceutical composition that comprises SARM compound and 5-alpha reductase inhibitor.In another embodiment, the invention provides combination and the pharmaceutical composition that comprises SARM compound and aromatase inhibitor.In another embodiment, the invention provides combination and the pharmaceutical composition that comprises SARM compound and progesterone.In another embodiment, the invention provides the composition and the pharmaceutical composition of the medicine that comprises the SARM compound and work by other nuclear hormone receptor.

One of ordinary skill in the art would recognize that the present invention is not limited to above-mentioned the content of specifically listing and describing.On the contrary, scope of the present invention is defined by following claim.

Claims

1, SARM (SARM) compound represented of the structure of formula I:

Wherein

X is a key, O, CH ₂, NH, Se, PR, NO or NR;

G is O or S;

R ₁Be CH ₃, CH ₂F, CHF ₂, CF ₃, CH ₂CH ₃, or CF ₂CF ₃

T be OH, OR ,-NHCOCH ₃, or NHCOR;

A is selected from following ring:

B is selected from following ring:

Wherein A and B can not be phenyl ring simultaneously;

Z is NO ₂, CN, COOH, COR, NHCOR or CONHR;

Y is CF ₃, F, I, Br, Cl, CN CR ₃Or SnR ₃

Q ₁And Q ₂Be hydrogen, alkyl, F, Cl, Br, I, CF independently of each other ₃, CN CR ₃, SnR ₃, NR ₂, NHCOCH ₃, NHCOCF ₃, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH ₃, NHCSCF ₃, NHCSR NHSO ₂CH ₃, NHSO ₂R, OR, COR, OCOR, OSO ₂R, SO ₂R, SR,

Q ₃And Q ₄Be hydrogen, alkyl, F, Cl, Br, I, CF independently of each other ₃, CN CR ₃, SnR ₃, NR ₂, NHCOCH ₃, NHCOCF ₃, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH ₃, NHCSCF ₃, NHCSR NHSO ₂CH ₃, NHSO ₂R, OR, COR, OCOR, OSO ₂R, SO ₂R or SR;

W ₁Be O, NH, NR, NO or S; And

W ₂Be N or NO.

2, SARM (SARM) compound or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination represented of the structure of formula I:

Wherein

X is a key, O, CH ₂, NH, Se, PR, NO or NR;

G is O or S;

R ₁Be CH ₃, CH ₂F, CHF ₂, CF ₃, CH ₂CH ₃, or CF ₂CF ₃

T be OH, OR ,-NHCOCH ₃, or NHCOR;

A is selected from following ring:

B is selected from following ring:

Wherein A and B can not be phenyl ring simultaneously;

Z is NO ₂, CN, COOH, COR, NHCOR or CONHR;

Y is CF ₃, F, I, Br, Cl, CN CR ₃Or SnR ₃

W ₁Be O, NH, NR, NO or S; And

W ₂Be N or NO.

3, SARM compound as claimed in claim 1, wherein X is O.

4, SARM compound as claimed in claim 1, wherein G is O.

5, SARM compound as claimed in claim 1, wherein T is OH.

6, SARM compound as claimed in claim 1, wherein R ₁Be CH ₃

7, SARM compound as claimed in claim 1, wherein Z is NO ₂

8, SARM compound as claimed in claim 1, wherein Z is CN.

9, SARM compound as claimed in claim 1, wherein Y is CF ₃

10, SARM compound as claimed in claim 1, wherein Q ₁Be NHCOCH ₃

11, SARM compound as claimed in claim 1, wherein Q ₁Be F.

12, SARM compound as claimed in claim 1, its structure with formula Ia is represented:

13, SARM compound as claimed in claim 1, wherein A is:

14, SARM compound as claimed in claim 1, wherein A is:

15, SARM compound as claimed in claim 1, wherein A is:

16, SARM compound as claimed in claim 1, wherein A is:

Or

17, SARM compound as claimed in claim 1, wherein B is:

18, SARM compound as claimed in claim 1, wherein B is:

19, SARM compound as claimed in claim 1, wherein B is:

20, SARM compound as claimed in claim 1, wherein B is:

Or

21, a kind of composition, it comprises SARM compound as claimed in claim 1 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination, and suitable carriers or thinner.

22, a kind of pharmaceutical composition, it comprises SARM compound as claimed in claim 1 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of significant quantity, and pharmaceutically acceptable carrier, thinner or salt.

23, a kind of SARM compound and androgen receptor bonded method of making, it may further comprise the steps: androgen receptor is contacted with SARM compound as claimed in claim 1 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of androgen receptor bonded amount with making the SARM compound effectively.

24, spermatogenetic method in a kind of inhibition individuality, it may further comprise the steps: the androgen receptor of described individuality is contacted with SARM compound as claimed in claim 1 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of the amount that effectively suppresses the sperm generation.

25, a kind of male individual method of contraception that makes, it may further comprise the steps: thus effectively suppress SARM compound as claimed in claim 1 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination that described individual sperm produces the amount that causes described individual contraception to described individual administration.

26, a kind of methods of hormonal treatment, it may further comprise the steps: individual androgen receptor is contacted with SARM compound as claimed in claim 1 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of the amount that effectively causes the androgen-dependent illness to change.

27, a kind of hormone replacement therapy method, it may further comprise the steps: individual androgen receptor is contacted with SARM compound as claimed in claim 1 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of the amount that effectively causes the androgen-dependent illness to change.

28, the method with the individuality of hormone-related conditions is suffered from a kind of treatment, and it may further comprise the steps: the SARM compound as claimed in claim 1 from the amount that the androgen-dependent illness changes to described individual administration and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination that effectively cause.

29, the method for the individuality of prostate cancer is suffered from a kind of treatment, and it may further comprise the steps: SARM compound as claimed in claim 1 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of effectively treating the amount of described individual prostate cancer to described individual administration.

30, a kind of method of preventing individual prostate cancer, it may further comprise the steps: SARM compound as claimed in claim 1 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of effectively preventing the amount of described individual prostate cancer to described individual administration.

31, the method for prostate cancer development in a kind of individuality that delays to suffer from prostate cancer, it may further comprise the steps: effectively delay SARM compound as claimed in claim 1 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of the amount of prostate cancer development in the described individuality to described individual administration.

32, the method for prostate cancer recurrence in a kind of individuality that prevents to suffer from prostate cancer, it may further comprise the steps: effectively prevent SARM compound as claimed in claim 1 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of the amount of prostate cancer recurrence in the described individuality to described individual administration.

33, the method for prostate cancer recurrence in the individuality of prostate cancer is suffered from a kind of treatment, and it may further comprise the steps: to described individual administration effectively SARM compound as claimed in claim 1 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of the amount of prostate cancer recurrence in the described individuality of treatment.

34, the method for xeropthalmus in the individuality of xeropthalmus is suffered from a kind of treatment, and it may further comprise the steps: effectively treat SARM compound as claimed in claim 1 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of the amount of xeropthalmus in this individuality to described individual administration.

35, a kind of method of preventing xeropthalmus in the individuality, it may further comprise the steps: effectively prevent SARM compound as claimed in claim 1 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of the amount of xeropthalmus in this individuality to described individual administration.

36, the method for apoptosis in a kind of inducing cancer cell, it may further comprise the steps: SARM compound as claimed in claim 1 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of the amount of the apoptosis in making described cancer cells and effectively causing this cell contact.

37, SARM (SARM) compound represented of the structure of formula II:

Wherein

X is a key, O, CH ₂, NH, Se, PR, NO or NR;

G is O or S;

R ₁Be CH ₃, CH ₂F, CHF ₂, CF ₃, CH ₂CH ₃, or CF ₂CF ₃

T be OH, OR ,-NHCOCH ₃, or NHCOR;

B is selected from following ring:

Z is NO ₂, CN, COOH, COR, NHCOR or CONHR;

Y is CF ₃, F, I, Br, C1, CN CR ₃Or SnR ₃

Q ₁And Q ₂Be hydrogen, alkyl, F, Cl, Br, I, CF independently of each other ₃, CNCR ₃, SnR ₃, NR ₂, NHCOCH ₃, NHCOCF ₃, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH ₃, NHCSCF ₃, NHCSR NHSO ₂CH ₃, NHSO ₂R, OR, COR, OCOR, OSO ₂R, SO ₂R, SR,

Q ₃And Q ₄Be hydrogen, alkyl, F, C1, Br, I, CF independently of each other ₃, CN CR ₃, SnR ₃, NR ₂, NHCOCH ₃, NHCOCF ₃, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH ₃, NHCSCF ₃, NHCSR NHSO ₂CH ₃, NHSO ₂R, OR, COR, OCOR, OSO ₂R, SO ₂R or SR;

W ₁Be O, NH, NR, NO or S; And

W ₂Be N or NO.

38, SARM (SARM) compound or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination represented of the structure of formula II:

Wherein

X is a key, O, CH ₂, NH, Se, PR, NO or NR;

G is O or S;

R ₁Be CH ₃, CH ₂F, CHF ₂, CF ₃, CH ₂CH ₃, or CF ₂CF ₃

T be OH, OR ,-NHCOCH ₃, or NHCOR;

B is selected from following ring:

With

Z is NO ₂, CN, COOH, COR, NHCOR or CONHR;

Y is CF ₃, F, I, Br, Cl, CN CR ₃Or SnR ₃

W ₁Be O, NH, NR, NO or S; And

W ₂Be N or NO.

39, SARM compound as claimed in claim 37, wherein X is O.

40, SARM compound as claimed in claim 37, wherein G is O.

41, SARM compound as claimed in claim 37, wherein T is OH.

42, SARM compound as claimed in claim 37, wherein R ₁Be CH ₃

43, SARM compound as claimed in claim 37, wherein Z is NO ₂

44, SARM compound as claimed in claim 37, wherein Z is CN.

45, SARM compound as claimed in claim 37, wherein Y is CF ₃

46, SARM compound as claimed in claim 37, wherein Q ₁Be NHCOCH ₃

47, SARM compound as claimed in claim 37, wherein Q ₁Be F.

48, SARM compound as claimed in claim 37, its structure with formula III is represented:

49, SARM compound as claimed in claim 37, its structure with formula IV is represented:

50, SARM compound as claimed in claim 37, it is represented by following structure:

51, SARM compound as claimed in claim 37, it is represented by following structure:

52, SARM compound as claimed in claim 37, it is represented by following structure:

53, a kind of composition, it comprises SARM compound as claimed in claim 37 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination, and suitable carriers or thinner.

54, a kind of pharmaceutical composition, it comprises SARM compound as claimed in claim 37 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of significant quantity, and pharmaceutically acceptable carrier, thinner or salt.

55, a kind of SARM compound and androgen receptor bonded method of making, it may further comprise the steps: androgen receptor is contacted with SARM compound as claimed in claim 37 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of androgen receptor bonded amount with making the SARM compound effectively.

56, spermatogenetic method in a kind of inhibition individuality, it may further comprise the steps: the androgen receptor of described individuality is contacted with SARM compound as claimed in claim 37 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of the amount that effectively suppresses the sperm generation.

57, a kind of male individual method of contraception that makes, it may further comprise the steps: thus effectively suppress SARM compound as claimed in claim 37 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination that described individual sperm produces the amount that causes described individual contraception to described individual administration.

58, a kind of methods of hormonal treatment, it may further comprise the steps: individual androgen receptor is contacted with SARM compound as claimed in claim 37 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of the amount that effectively causes the androgen-dependent illness to change.

59, a kind of hormone replacement therapy method, it may further comprise the steps: individual androgen receptor is contacted with SARM compound as claimed in claim 37 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of the amount that effectively causes the androgen-dependent illness to change.

60, the method with the individuality of hormone-related conditions is suffered from a kind of treatment, and it may further comprise the steps: the SARM compound as claimed in claim 37 from the amount that the androgen-dependent illness changes to described individual administration and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination that effectively cause.

61, the method for the individuality of prostate cancer is suffered from a kind of treatment, and it may further comprise the steps: SARM compound as claimed in claim 37 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of effectively treating the amount of described individual prostate cancer to described individual administration.

62, a kind of method of preventing individual prostate cancer, it may further comprise the steps: SARM compound as claimed in claim 37 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of effectively preventing the amount of described individual prostate cancer to described individual administration.

63, the method for prostate cancer development in a kind of individuality that delays to suffer from prostate cancer, it may further comprise the steps: effectively delay SARM compound as claimed in claim 37 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of the amount of prostate cancer development in the described individuality to described individual administration.

64, the method for prostate cancer recurrence in a kind of individuality that prevents to suffer from prostate cancer, it may further comprise the steps: effectively prevent SARM compound as claimed in claim 37 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of the amount of prostate cancer recurrence in the described individuality to described individual administration.

65, the method for prostate cancer recurrence in the individuality of prostate cancer is suffered from a kind of treatment, and it may further comprise the steps: to described individual administration effectively SARM compound as claimed in claim 37 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of the amount of prostate cancer recurrence in the described individuality of treatment.

66, the method for xeropthalmus in the individuality of xeropthalmus is suffered from a kind of treatment, and it may further comprise the steps: effectively treat SARM compound as claimed in claim 37 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of the amount of xeropthalmus in this individuality to described individual administration.

67, a kind of method of preventing xeropthalmus in the individuality, it may further comprise the steps: effectively prevent SARM compound as claimed in claim 37 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of the amount of xeropthalmus in this individuality to described individual administration.

68, the method for apoptosis in a kind of inducing cancer cell, it may further comprise the steps: the SARM compound as claimed in claim 37 of the amount of the apoptosis in making described cancer cells and effectively causing this cell and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination contact.

69, SARM (SARM) compound represented of the structure of formula V:

Wherein

X is a key, O, CH ₂, NH, Se, PR, NO or NR;

G is O or S;

R ₁Be CH ₃, CH ₂F, CHF ₂, CF ₃, CH ₂CH ₃, or CF ₂CF ₃

T be OH, OR ,-NHCOCH ₃, or NHCOR;

A is selected from following ring:

With

Z is NO ₂, CN, COOH, COR, NHCOR or CONHR;

Y is CF ₃, F, I, Br, Cl, CN CR ₃Or SnR ₃

W ₁Be O, NH, NR, NO or S; And

W ₂Be N or NO.

70, SARM (SARM) compound or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination represented of the structure of formula V:

Wherein

X is a key, O, CH ₂, NH, Se, PR, NO or NR;

G is O or S;

R ₁Be CH ₃, CH ₂F, CHF ₂, CF ₃, CH ₂CH ₃, or CF ₂CF ₃

T be OH, OR ,-NHCOCH ₃, or NHCOR;

A is selected from following ring:

With

Z is NO ₂, CN, COOH, COR, NHCOR or CONHR;

Y is CF ₃, F, I, Br, Cl, CN CR ₃Or SnR ₃

W ₁Be O, NH, NR, NO or S; And

W ₂Be N or NO.

71, as the described SARM compound of claim 69, wherein X is O.

72, as the described SARM compound of claim 69, wherein G is O.

73, as the described SARM compound of claim 69, wherein T is OH.

74, as the described SARM compound of claim 69, wherein R ₁Be CH ₃

75, as the described SARM compound of claim 69, wherein Z is NO ₂

76, as the described SARM compound of claim 69, wherein Z is CN.

77, as the described SARM compound of claim 69, wherein Y is CF ₃

78, as the described SARM compound of claim 69, wherein Q ₁Be NHCOCH ₃

79, as the described SARM compound of claim 69, wherein Q ₁Be F.

80, as the described SARM compound of claim 69, its structure in order to following formula VI is represented:

81, as the described SARM compound of claim 69, it is represented by following structure:

82, as the described SARM compound of claim 69, it is represented by following structure:

83, as the described SARM compound of claim 69, it is represented by following structure:

84, as the described SARM compound of claim 69, it is represented by following structure:

85, as the described SARM compound of claim 69, it is represented by following structure:

86, as the described SARM compound of claim 69, it is represented by following structure:

Or

87, as the described SARM compound of claim 69, it is represented by following structure:

Or

88, as the described SARM compound of claim 69, it is represented by following structure:

Or

89, as the described SARM compound of claim 69, it is represented by following structure:

Or

90, a kind of composition, it comprises as the described SARM compound of claim 69 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination, and suitable carriers or thinner.

91, a kind of pharmaceutical composition, it comprises as the described SARM compound of claim 69 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination, and pharmaceutically acceptable carrier, thinner or salt.

92, a kind of SARM compound and androgen receptor bonded method of making, it may further comprise the steps: make androgen receptor and make contacting as the described SARM compound of claim 69 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of SARM compound and androgen receptor bonded amount effectively.

93, spermatogenetic method in a kind of inhibition individuality, it may further comprise the steps: the androgen receptor that makes described individuality with effectively suppress contacting of amount that sperm produces as the described SARM compound of claim 69 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination.

94, a kind of male individual method of contraception that makes, it may further comprise the steps: thereby to described individual administration effectively suppress described individual sperm produce the amount that causes described individual contraception as the described SARM compound of claim 69 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination.

95, a kind of methods of hormonal treatment, it may further comprise the steps: make the androgen receptor of individuality and contacting as the described SARM compound of claim 69 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of the amount that effectively causes the androgen-dependent illness to change.

96, a kind of hormone replacement therapy method, it may further comprise the steps: make the androgen receptor of individuality and contacting as the described SARM compound of claim 69 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of the amount that effectively causes the androgen-dependent illness to change.

97, the method with the individuality of hormone-related conditions is suffered from a kind of treatment, and it may further comprise the steps: to described individual administration effectively cause amount that the androgen-dependent illness changes as the described SARM compound of claim 69 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination.

98, the method for the individuality of prostate cancer is suffered from a kind of treatment, and it may further comprise the steps: to described individual administration effectively the described individual prostate cancer of treatment amount as the described SARM compound of claim 69 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph or crystal or their arbitrary combination.

99, a kind of method of preventing individual prostate cancer, it may further comprise the steps: to described individual administration effectively the described individual prostate cancer of prevention amount as the described SARM compound of claim 69 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination.

100, the method for prostate cancer development in a kind of individuality that delays to suffer from prostate cancer, it may further comprise the steps: to described individual administration effectively delay prostate cancer development in the described individuality amount as the described SARM compound of claim 69 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination.

101, the method for prostate cancer recurrence in a kind of individuality that prevents to suffer from prostate cancer, it may further comprise the steps: to described individual administration effectively prevent prostate cancer recurrence in the described individuality amount as the described SARM compound of claim 69 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination.

102, the method for prostate cancer recurrence in the individuality of prostate cancer is suffered from a kind of treatment, and it may further comprise the steps: to described individual administration effectively in the described individuality of treatment the amount of prostate cancer recurrence as the described SARM compound of claim 69 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination.

103, the method for xeropthalmus in the individuality of xeropthalmus is suffered from a kind of treatment, and it may further comprise the steps: to described individual administration effectively treat xeropthalmus in this individuality amount as the described SARM compound of claim 69 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination.

104, a kind of method of preventing xeropthalmus in the individuality, it may further comprise the steps: to described individual administration effectively prevent xeropthalmus in this individuality amount as the described SARM compound of claim 69 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination.

105, the method for apoptosis in a kind of inducing cancer cell, it may further comprise the steps: the contacting as the described SARM compound of claim 69 and/or its analogue, derivative, isomer, metabolite, pharmacologically acceptable salts, medicine, hydrate, N-oxide compound, prodrug, polymorph, crystal or their arbitrary combination of the amount of the apoptosis in making described cancer cells and effectively causing this cell.